Trehalose compound and pharmaceutical comprising the compound
The object of the present invention is to provide a novel trehalose compound having a high affinity for an adenosine A3 receptor. The trehalose compound of the present invention is represented by General Formula (1): wherein X and X′ represent a hydrogen atom, and the like; Y and Y′ independently represent an oxygen atom, and the like; R 1 and R 2 independently represent a C 1 -C 6 alkyl group; and R 3 and R 4 independently represent a C 3 -C 6 alkyl group. The trehalose compound of the present invention has a remarkably high affinity for an adenosine A3 receptor.
1. A trehalose compound represented by General Formula (1):
wherein X and X′ are the same or different, and each represent a hydrogen atom, a hydroxy group, or a C 1 -C 6 alkoxy group;
Y and Y′ are the same or different, and each represent an oxygen atom or —NR 5 — wherein R 5 represents a hydrogen atom or a C 1 -C 6 alkyl group;
R 1 and R 3 each represent a C 1 -C 7 alkyl group; and
R 2 and R 4 each represent a C 3 -C 6 alkyl group.
2. The trehalose compound according to claim 1 , wherein X and X′ are both hydrogen atoms.
3. The trehalose compound according to claim 1 , wherein X and X′ are both hydroxy groups.
4. The trehalose compound according to claim 1 , wherein X and X′ are both methoxy groups.
5. The trehalose compound according to claim 4 , wherein Y and Y′ are both oxygen atoms.
6. The trehalose compound according to claim 4 , wherein Y and Y′ are both —NH—.
7. The trehalose compound according to claim 6 , wherein R 1 and R 3 are both n-hexyl groups.
8. The trehalose compound according to claim 6 , wherein R 2 and R 4 are both n-pentyl groups.
9. The trehalose compound according to claim 1 , which is selected from the group consisting of:
6,6′-bis-N-(2-pentylnonanoylamino)-6,6′-dideoxy-α,α′-trehalose;
6,6′-bis-O-(2-pentylheptanoyl)-α,α′-trehalose;
6,6′-bis-N-[(2R,3R)-3-methoxy-2-pentylnonanolyamino]-6,6′-dideoxy-α,α′-trehalose;
6,6′-bis-O-[(2R,3R)-3-methoxy-2-pentylnonanoyl]-α,α′-trehalose;
6,6′-bis-O-[(2R,3S)-3-hydroxy-2-pentylnonanoyl]-α,α′-trehalose;
6,6′-bis-O-[(2R,3R)-3-hydroxy-2-pentylnonanoyl]-α,α′-trehalose;
6,6′-bis-O-[(2S,3S)-3-hydroxy-2-pentylnonanoyl]-α,α′-trehalose;
6-O-[(2R,3R)-3-hydroxy-2-pentylnonanoyl]-6′-O-[(2S,3S)-3-hydroxy-2-pentylnonanoyl]-α,α′-trehalose; and
6,6′-bis-O-[(2S,3R)-3-hydroxy-2-pentylnonanoyl]-α,α′-trehalose.
10. A pharmaceutical composition comprising the trehalose compound according to claim 1 .
11. An adenosine A3 receptor antagonist composition comprising the trehalose compound according to claim 1 .